ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Retail Trade

Sundrug Co., Ltd.

  • 3,195.00 JPY
  • -40.00
  • -1.24%
  • Japan
    Mar 22, 2019
  • Ticker
    TKS(9989)
  • Prev. close
    3,235
  • Market cap (JPY)
    386,036.37M
  • Market cap (USD)
    3,493.06M
  • Shares
    119.33M

Business Summary

Sundrug Co., Ltd. engages in the pharmaceutical business. It operates through the Drug Store and Discount Store segments. The Drug Store segment sells pharmaceutical products, cosmetics, and general merchandise. The Discount Store segment offers household goods and food products. The company was founded by Yukimasa Tada in December 1957 and is headquartered in Fuchu, Japan.

Financial Highlights

Mar 2018 JPYUSD
Revenue564,215M5,090.70M
Gross Profit140,959M1,271.82M
Operating income36,081M325.54M
Income before tax36,598M330.21M
Net income24,829M224.02M
EBITDA43,869M395.81M
Diluted EPS212.301.91
Dividends Per Share600.54
Total Assets246,619M2,318.93M
Total liabilities91,789M863.08M
Total equity154,828M1,455.83M
Operating cash flow36,148M326.15M
Currency in JPYCurrency in USD

Historical Data

 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 447,819M 445,818M 503,773M 528,394M 564,215M
Gross Profit 105,845M 108,236M 124,119M 130,748M 140,959M
Operating income 28,057M 25,924M 33,025M 34,056M 36,081M
Income before tax 27,178M 26,569M 33,277M 34,424M 36,598M
Net income 15,754M 16,362M 21,569M 23,312M 24,829M
EBITDA 33,666M 32,149M 39,444M 41,335M 43,869M
Diluted EPS 124.98 133.47 178.42 197.31 212.30
Dividends Per Share 28 30 42.50 50 60
Total Assets 192,636M 190,171M 217,507M 221,458M 246,619M
Total liabilities 79,431M 74,184M 84,223M 85,121M 91,789M
Total equity 113,205M 115,987M 133,284M 136,335M 154,828M
Operating cash flow 32,321M 12,829M 33,574M 28,226M 36,148M
 Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018
Revenue 4,470.52M 4,058.18M 4,195.16M 4,879.54M 5,090.70M
Gross Profit 1,056.63M 985.24M 1,033.59M 1,207.41M 1,271.82M
Operating income 280.08M 235.98M 275.01M 314.49M 325.54M
Income before tax 271.31M 241.85M 277.11M 317.89M 330.21M
Net income 157.27M 148.93M 179.61M 215.27M 224.02M
EBITDA 336.08M 292.64M 328.46M 381.71M 395.81M
Diluted EPS 1.24 1.21 1.48 1.82 1.91
Dividends Per Share 0.27 0.27 0.35 0.46 0.54
Total Assets 1,870.52M 1,585.74M 1,935.20M 1,987.41M 2,318.93M
Total liabilities 771.28M 618.58M 749.34M 763.89M 863.08M
Total equity 1,099.23M 967.16M 1,185.85M 1,223.50M 1,455.83M
Operating cash flow 322.65M 116.77M 279.58M 260.65M 326.15M

Valuation Measures

Mar 2018
PER23.15
ROA10.60%
ROE17.05%
Operating margin6.39%
Profit margin4.40%

Key executives

  • Chairman & President: Tatsuro Saitsu
  • Director & Manager-Store Development: Yoshimitsu Sakai
  • Director & General Manager-Sales: Kazuhiro Tsuruta
  • Manager-Administration: Yoshinobu Kato

Shareholders

  • TADA NAOKI /SUNDRUG/ (39.2%)
  • Massachusetts Financial Services Co. (9.5%)
  • Fidelity Management & Research Co. (4.0%)
  • Sundrug Co., Ltd. (2.0%)
  • TADA TAKASHI (1.8%)
  • The Vanguard Group, Inc. (1.4%)
  • Nomura Asset Management Co., Ltd. (1.2%)
  • Norges Bank Investment Management (1.0%)
  • BlackRock Fund Advisors (0.9%)
  • MFS Investment Management K.K. (0.7%)

Contact Details

Related Companies

  • Sundrug Plus KK
  • Sundrug Tokai KK
  • Sun Drug Pharmacies KK
  • Seikoudo Yakkyoku KK
  • DIREX Corp.
  • Act KK

Competitors

  • cocokara fine Inc.
Last Updated on 22 Mar, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media